SAN DIEGO , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Sarah Cooley , M.D., M.S., a leading expert inRead All »
SAN DIEGO , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Dan Shoemaker , Ph.D., Chief Scientific Officer,Read All »
FT516 Off-the-Shelf NK Cell Cancer Immunotherapy Cleared for Clinical Investigation by FDA Product Candidate Derived from Clonal Master iPSC Line Engineered with Novel CD16 Fc Receptor Clinical Trial to Evaluate Multi-dose Cycles of FT516 for Treatment of Hematologic Malignancies, including inRead All »
FT500, First-ever iPSC-derived Cell Product Candidate Cleared for U.S. Clinical Investigation by FDA, Featured in Oral Presentation SAN DIEGO , Dec. 04, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development ofRead All »
Agreement with Max Delbrück Center Provides Access to Broad Intellectual Property Portfolio of Humanized Antibody Fragments and Antigen-Binding Domains Targeting BCMA SAN DIEGO , Dec. 03, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical companyRead All »
Company to Initiate First-ever U.S. Clinical Investigation of iPSC-derived Cell Product FT500 to be Featured in Oral Presentation on Monday, December 3 at ASH Annual Meeting SAN DIEGO , Nov. 30, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceuticalRead All »
NK100 Shows Clinical Benefit in Treating Advanced Hematologic Malignancies and Solid Tumors Disease Control Shown in All Subjects Re-treated with Second Dose of NK100 No NK100-related Dose Limiting Toxicities Reported Submitted Data to FDA Demonstrating FT500 Master iPSC Bank is Free ofRead All »
SAN DIEGO , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko , President and Chief ExecutiveRead All »
Twenty Subjects Treated across Three Phase 1 Studies of FATE-NK100 Entered into Off-the-Shelf, iPSC-derived CAR-T Cell Collaboration with ONO Pharmaceutical Completed $144M Common Stock Public Offering Three Oral and Four Poster Presentations Covering Product Pipeline will be Presented at ASHRead All »
Three Oral and Four Poster Presentations Covering Product Pipeline Accepted for Presentation Company to Host Investor Event at ASH on November 30 SAN DIEGO , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to theRead All »
DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.